PathKey.AI (ASX:PKY) is an ASX-listed Artificial Intelligence (AI) company that recently acquired Singapore-based Chipforge, which aims to speed up the design process for semiconductors by using AI agents to undertake the time-intensive and costly part of the chip design process for this US$1 trillion industry. PathKey is simultaneously commercialising TrialKey, an AI-driven clinical trial optimisation and success prediction platform